90% mortality rate. In this study, Ebola virus like particles (EVLPs) and the aglycosyl
subfragment of glycoprotein (GP1 subfragment D) were used to generate monoclonal
antibodies (MAbs) against different epitopes of the viral antigens. Such MAbs could be
useful in diagnostics and potential therapeutics of viral infection and its hemorrhagic
symptoms. Hybridoma cell fusion technology was used for production of MAbs. The MAbs …